First patient dosed in first-in-human Phase l – lla clinical study with CB-103

First dosing of cancer patients in first-in-human Phase l – lla clinical study with CB-103 started in December 2017.

Regulatory approval of the Phase I-IIA study for CB-103 by Swissmedic

Chairman of the Strategic Advisory Board appointed